Expedited partner therapy for Chlamydia trachomatis at the community pharmacy
|
|
- Julianna Marsh
- 5 years ago
- Views:
Transcription
1 DOI: /j x Genitourinary medicine Expedited partner therapy for Chlamydia trachomatis at the community pharmacy ST Cameron, a,b A Glasier, a,b A Muir, c G Scott, d A Johnstone, a,b H Quarrell, a C Oroz, a,e M McIntyre, f D Miranda, a G Todd g a Dean Terrace Centre, NHS Lothian, Edinburgh, UK b Department of Reproductive and Developmental Sciences, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK c Department of Public Health, NHS Lothian, Edinburgh, UK d Department of Genitourinary Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK e Genitourinary Medicine Clinic, Howden Health Centre, Livingston, West Lothian, UK f Richard Verney Health Centre, Edinburgh, UK g Pharmacy Department, Roodlands Hospital, NHS Lothian, Haddington, East Lothian, UK Correspondence: Dr ST Cameron, Consultant Gynaecologist, 18 Dean Terrace, Edinburgh EH4 1NL, UK. Sharon.Cameron@ed.ac.uk Accepted 16 March Published Online 25 May Objective Expedited partner treatment (EPT) for uncomplicated Chlamydia trachomatis at the pharmacy is an alternative approach to partner notification that has not yet been evaluated within the UK. The aim of this study was to evaluate EPT for partners using pharmacies in Lothian. Design A pilot study over 18 months. Setting Selected healthcare settings and community pharmacies in Lothian, Scotland, UK. Population Sexual partners of index cases with uncomplicated C. trachomatis. Methods Index cases with uncomplicated C. trachomatis were given a pharmacy voucher to pass onto sexual partners. Partners could redeem vouchers for free treatment (azithromycin) at one of 90 pharmacies in the area. Main outcome measures The main outcome measure was the proportion of vouchers redeemed. Secondary outcomes included patient satisfaction, as determined at a telephone follow-up of a subgroup of female index cases from one study site, 1 month later. Results In total 577 vouchers were issued to chlamydia-positive index patients of mean age 22.9 years (range years). A total of 231 vouchers were redeemed (40%), at a median of 2 days after issue. Only 4% of partners attended a clinic for treatment. Most index patients surveyed reported that partners were satisfied with this method of treatment (48 out of 55; 87%). Conclusions Expedited partner treatment for uncomplicated chlamydia at a pharmacy is a popular choice, and increases options on where, when and how partners are treated. Keywords Chlamydia trachomatis, expedited partner therapy, partner notification, pharmacy. Please cite this paper as: Cameron S, Glasier A, Muir A, Scott G, Johnstone A, Quarrell H, Oroz C, McIntyre M, Miranda D, Todd G. Expedited partner therapy for Chlamydia trachomatis at the community pharmacy. BJOG 2010;117: Introduction In the past decade, advances have been made for the detection and treatment of uncomplicated chlamydia infection, with more sensitive tests and single-dose antibiotic treatment regimes. However, strategies to ensure sexual contacts are treated remain largely unchanged. Partner notification is the traditional means for arranging partner treatment. This usually involves partner attendance at a genitourinary medicine (GUM) clinic, where specialised staff offer testing and may give empirical epidemiological treatment at the same time. 1 However, partners may be deterred from attending a GUM clinic because of the stigma associated with having a sexually transmitted infection (STI). 2 Delay in seeking treatment may be further compounded by the difficulty of access to general practice (GP) surgeries and GUM clinics, especially at weekends and evenings. Timely treatment of sex partners is important to prevent index patients from reinfection as a consequence of the resumption of sex with an untreated partner. Reinfection in women is believed to increase the likelihood of complications such as tubal infertility. 3 One strategy to expedite partner treatment is patient-delivered partner therapy (PDPT). 4 This involves the index patient delivering a dose of anti-chlamydial therapy to each sexual partner. Large randomised controlled trials (RCTs) in the USA and UK 1074 ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
2 Pharmacy treatment for chlamydia have shown that it is as least as effective as patient referral, both in terms of reinfection rates in index patients and in the proportion of sexual contacts treated. 5 7 Although permitted in 20 states within the USA, 4 adopting the PDPT approach in the UK would require legislative change to permit clinicians to administer antibiotics for an individual they have not met and been able to evaluate. At present, therefore, use of PDPT within the UK is not recommended outwith the confines of a tightly controlled research study. 7 An alternative approach is that of expedited partner treatment (EPT) at a pharmacy. Increasing numbers of pharmacies have private interview rooms, and pharmacists are well placed to interview a patient about their medical history and any contraindications to antibiotic therapy, and to identify possible drug interactions with other medicines that the individual may be taking. Furthermore, attending the pharmacist for treatment could arguably be less stigmatising than attending a clinic or GP. In a recent survey in Lothian, community pharmacists were overwhelmingly positive towards providing a treatment service for individuals or sexual contacts with uncomplicated chlamydia. 8 We therefore decided to undertake a pilot study within NHS Lothian (Edinburgh and surrounding area), designed to evaluate partner treatment at community pharmacies as an additional choice to treatment at family planning clinics, GUM clinics or at the GP. As part of this project, entitled NHS Pharmacy Direct, index patients who had been treated for Chlamydia trachomatis (uncomplicated) at selected health service sites in Lothian were given a pharmacy treatment voucher to pass on to their sexual partner(s). These partners could redeem the voucher for free treatment (single 1-g dose of azithromycin) at participating pharmacies, if they wished to do so, unless they preferred to attend a clinic or their GP for treatment. The main outcome of the study was the proportion of pharmacy vouchers that were redeemed. Secondary outcomes were satisfaction with the voucher scheme and voucher use by different clinical populations. Methods A total of 90 pharmacies across Lothian agreed to participate (out of a total of the 179 pharmacies invited to take part) in NHS Pharmacy Direct, and to provide free treatment to individuals upon receipt of a study voucher. Five selected health service sites throughout Lothian took part between December 2007 and May Four of the sites were city centre sites in Edinburgh: a family planning clinic (FPC), a hospital termination of pregnancy clinic (TOP), a university student health service (GP) and a GUM clinic. The fifth site was a GUM clinic in West Lothian. At all five sites index cases (men and women with uncomplicated C. trachomatis only, i.e. no other STIs) were treated, and received both written and verbal information about chlamydia and the importance of partner treatment (sexual partners from within the past 6 months). Index cases were then given a pharmacy treatment voucher for each sexual partner (within the last 6 months) that partners could take to a participating pharmacy and redeem for free treatment. The voucher stated that the bearer was a partner of an individual with chlamydia infection who should be treated immediately with 1 g of azithromycin orally (as per Lothian Formulary guidelines). The reverse of the voucher listed the names, addresses and phone numbers of all the pharmacies that had agreed to participate. Vouchers were only given to those individuals with at least one contactable partner who had not already been treated, and who was resident in Lothian. All vouchers had a unique number that was recorded and matched with the index case identifying number in order to provide data on partner notification rates. At all sites except TOP and GUM clinics in West Lothian, the reasons for not issuing vouchers to chlamydia-positive individuals were recorded. At GUM clinics, both male and female index cases were given vouchers, but all other sites treated only female index cases. Vouchers were not given to men who have sex with men (MSM), as they were felt to constitute a high-risk group for co-morbidities that should be managed at a specialist GUM clinic. At all sites vouchers could be issued by all medical and nursing staff responsible for managing patients with chlamydia infection. Index cases were also given a leaflet for sexual partners that provided contact details for clinics that offered testing and treatment should they prefer to be treated at a clinic. The leaflet also advised that anyone with pelvic pain, vaginal or penile discharge or dysuria, or who was currently pregnant should attend a doctor instead of a pharmacy. On presentation of the voucher, pharmacists would check that the individual had no contraindications to azithromycin before dispensing this via a patient group direction (PGD). The voucher was later returned to the coordinating study nurse. Pharmacists also gave individuals a chlamydia information leaflet that contained details of GUM and FPC clinics where STI testing could be performed. All participating pharmacists were familiar with the requirements of PGDs, and all had received written information about the study and chlamydia, together with information leaflets about chlamydia for patients, in advance of the study commencing. In addition, information on chlamydia for pharmacists was available via NHS Education Scotland. 9 For further information or advice, pharmacists could contact the study investigators. As part of this project, pharmacies received a 5 fee for treating each sexual partner, plus the corresponding British National Formulary cost for azithromycin. ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1075
3 Cameron et al. Data was thus available on the proportion of vouchers that were issued from each study site, the number of vouchers redeemed and the date of redemption, the pharmacies used and the proportion of index patients whose partners opted for treatment in this way. In addition, at the FPC and both GUM clinics, an audit of case records was conducted to determine the proportion of partners who attended the FPC or GUM clinics for treatment rather than using the Pharmacy Direct voucher. At the FPC, a survey of patient satisfaction with the voucher scheme was conducted by telephone 1 month after treatment among women issued with a voucher between May 2008 and June Women were asked if they had given the vouchers to their partners, if their partners had used the voucher for treatment, and if so, how acceptable their partners found this method of treatment. Women that did not respond were deemed lost to follow-up after three unsuccessful telephone calls. The study protocol was reviewed by the chair of one of the Lothian research ethics committees, who confirmed that ethical committee Table 1. Reasons why clinical staff did not issue vouchers to 235 out of 1047 (22%) chlamydia-positive index cases (family planning clinic, student GP clinic and genitourinary medicine clinic in the city centre) n = 235 n (%) Partner not contactable/refuses contact 81 (34) Partner already treated 63 (27) Partner not in Lothian 43 (18) Index case declined voucher 27 (11) Provider referral 18 (8) Other 3 (1) Patient-delivered partner therapy 2 Partner pregnant 1 approval was not required for this health services research project. Statistical analysis Comparison of voucher use between groups was performed using chi-square tests, using spss. Results Voucher issue During the 18 months of the study, a total of 577 vouchers were issued to chlamydia-positive index patients. This represented 63% of all eligible patients at the non-gum sites (304 vouchers issued out of 482 patients who tested positive), compared with 20% at the GUM sites (273 vouchers issued out of 1340 patients who tested positive); P < Reasons for not issuing vouchers were recorded for 235 of the 1047 (22%) index cases. The commonest reasons recorded for non-issue are shown in Table 1. Index patients who were issued with vouchers were of mean age 22.9 years (range years) (Table 2). Most vouchers were given to female index patients (n = 392 vouchers; 68%). At GUM sites 23% (n = 133) of the total number of vouchers issued were given to male index patients. The sex of the index patient was not recorded in the remaining 52 patients (9%). Data on the total number of vouchers issued per index patient were recorded in 73% of cases (423 out of 577). The median number of vouchers issued was one per index case (range 1 4 vouchers), with 12% of index patients receiving more than one voucher. Voucher redemption In total 231 vouchers (40%) were redeemed at pharmacies. The highest voucher redemption rates were observed for vouchers issued from the FPC, but this difference did not reach statistical significance (Table 2) (P = 0.059). Voucher Table 2. Number of vouchers issued at each site, proportion of vouchers redeemed and proportion of partners choosing to be treated at a clinic Site Sex of index patient Mean age in years (range) of index patients No. of vouchers issued Vouchers redeemed n (%) Partners treated at clinic n (%) Family planning clinic Female 24.9 (15 47) (52) 1 (1) Genitourinary medicine clinic (city centre) Male and female 23.3 (16 46) (38) 10 (4) Genitourinary medicine clinic (West Lothian) Male and female 23.2 (16 43) (40) 4 (13) Termination of pregnancy clinic Female 21.2 (15 41) (34) NK Student general practice clinic Female 21.8 (19 28) (45) NK Total 22.9 (15 47) (40) 15 (4) NK, not known. There was no statistically significant difference in voucher redemption rates between sites (P = 0.059) ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
4 Pharmacy treatment for chlamydia redemption by partners of male index cases (presumed to be female) was 41% (55 redeemed out of 133 vouchers issued), and did not differ significantly from that of partners of female index cases (presumed male), which was 45% (176 redeemed out of 392 issued); P = The time to redemption of the voucher was a median of 2 days after issue (range days). The majority of participating pharmacies (57 out of 90; 63%) were used by partners. Partners choosing to attend a clinic rather than use voucher Only 15 partners out of a total of 375 at the sites audited (4%) chose to be treated at a GUM or FPC clinic (Table 2). Index patient and partner satisfaction The patient satisfaction survey was conducted over 13 months among 67 consecutive index patients, who received a total of 79 vouchers (corresponding to 60% of the total vouchers issued at the FPC). A total of 60 of these 67 women responded to telephone contact (90%). Most women (n = 55; 92%) stated that they had given a voucher to at least one partner. In the five cases where women stated that they did not pass on vouchers, this was because the partner attended a clinic for treatment (n = 2), the partner refused the voucher (n = 1), the index case had not yet made contact with the partner (n = 1) or the index case had lost the voucher (n = 1). Most of the 55 index cases (n = 48; 87%) reported that partners were either very satisfied (n = 27; 49%) or quite satisfied (n = 21; 38%) with treatment in this way. Two women reported that partners were neutral about treatment in this way (4%), and the remaining five women stated that they did not know how satisfied their partners were (9%). Of these 55 women who delivered vouchers to partners, the vouchers were actually redeemed in 34 cases (62%), in a median of 3 days (range 0 78 days). The voucher that was reported as lost by the index patient at the 1-month telephone contact was redeemed 78 days after issue. Index patients were asked how satisfied they were themselves with having a voucher to pass onto partners in this way. Out of the 60 respondents, most (46; 77%) stated that they were either very satisfied (n = 24; 40%) or quite satisfied (n = 22; 37%). Five women were neutral (8%) about satisfaction, and eight women did not know how satisfied they were (13%). The one woman who lost the voucher was very dissatisfied (2%) with this type of treatment. Discussion This pilot study demonstrated that, when given the option, a high proportion (40%) of partners of patients with uncomplicated chlamydia chose to be treated at a pharmacy rather than attend a clinic. This figure is likely to be an underestimate of the actual proportion of contacts that would choose to be treated in this way, as index patients did not always pass on vouchers to their partners. Vouchers were redeemed a median of 2 days after index patients received them, which compares favourably with waiting times for an appointment at a specialist clinic or with a GP. In our recent RCT of different strategies for treating male partners of women with chlamydia, namely standard patient referral to a GUM clinic, the use of a postal testing kit or PDPT, we demonstrated that 19%, 23% and 32% of partners were actually treated by these interventions, respectively. 7 So the 40% voucher redemption rate in this current study shows that treatment of partners at a pharmacy results in a favourable treatment rate. In the current study only 4% of partners from patients attending a GUM or FPC clinic, chose to be treated at a clinic rather than use the vouchers, compared with 18% of partners who were known to have chosen to attend a clinic rather than use PDPT in our earlier RCT. 7 The pharmacy voucher treatment scheme overcomes any safety concerns of PDPT, as recipients are questioned by the pharmacists to ensure that those with known allergies or contraindications to azithromycin do not receive the medication. Furthermore, pharmacy treatment would appear to overcome the legislative and regulatory difficulties that currently impede the clinical use of PDPT in the UK. 7,11 In this pilot study, partners were treated without testing for chlamydia. One criticism of this approach to managing partners is that it removes the opportunity to test partners for chlamydia and other STIs. Partner testing is thought to be important, as failure to confirm chlamydia positivity is thought to reduce the likelihood that other sexual contacts the partner may have had will be notified and treated. 10 However, in a previous study we showed that detection of secondary contacts was inefficient in this population. 7 Clearly, however, partner testing for chlamydia at the pharmacy has been shown to be feasible, 12 and could easily be incorporated into a voucher treatment scheme, although this would add significantly to the cost. Alternatively, as nucleic acid amplification tests for C. trachomatis may remain positive for up to 6 weeks after treatment, partners can still choose to be treated at the pharmacy and subsequently attend a clinic for testing if they wished to do so. With regards to testing partners for other STIs, a previous study in Lothian showed that there were no cases of gonorrhoea, syphilis or HIV detected, out of 488 partners of women with C. trachomatis attending a GUM clinic. 13 Thus, the value of testing partners for other STIs may depend upon the prevalence within the community. It was interesting in this study that 45% of partners (presumed male) of female index cases chose to use the ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1077
5 Cameron et al. pharmacy voucher. This is in contrast to the findings of a previous questionnaire survey of men in Lothian who seemed to prefer (at least in theory) to attend a clinic for testing. 14 Women who were surveyed in our telephone interviews at the FPC site reported high levels of satisfaction with the voucher scheme. Chlamydia-positive women have previously reported overwhelming enthusiasm towards the theoretical possibility of delivering antibiotics directly to partners. 14 Whereas the small group of respondents in our current survey may, or may not, reflect the views of the larger population, nevertheless this does give some indication that expedited partner treatment via a pharmacy may also be acceptable to women. This study was a pragmatic study, and all staff (medical and nursing) who were responsible for managing chlamydia-positive patients issued vouchers. We believe therefore that the findings of this study are likely to reflect what would happen if this pharmacy voucher scheme or expedited partner therapy at the pharmacy were to be adopted into everyday clinical practice. The lower voucher issue rate at GUM clinics is interesting. This may represent more complex cases attending specialist GUM settings, and/or differences in staff skills or acceptability towards this form of treatment. These findings suggest that this partner treatment strategy may be particularly useful outside GUM settings, where the majority of C. trachomatis infection in women in Scotland is now being diagnosed. 15 Given the increasing workload that has been recorded at GUM clinics throughout Scotland, pharmacy treatment of uncomplicated C. trachomatis may also help to ease the burden that management of this condition places upon specialist services. 15 Clearly, not all partners chose to use the voucher, and not all index patients were issued with vouchers, highlighting that pharmacy voucher treatment cannot replace traditional partner notification and patient referral to specialist clinics. It does, however, add choice for patients on where, when and how they are treated. Furthermore, it may improve access to timely treatment, which is important in preventing reinfection through the resumption of sex with untreated partners. Further larger studies of expedited partner therapy at the pharmacy that include the determination of repeat infection rates and a cost economic analysis are therefore warranted. Disclosure of interests None to declare. Contribution to authorship STC, AG, AM and GS designed the study and contributed to the writing of the paper. AJ, HQ, CO, MM and DM conducted the study and audits. GT and AM designed the PGD used in the study. All authors approved the final version. Details of ethics approval The study protocol was reviewed by the chair of one of the Lothian research ethics committees, who confirmed that ethical committee approval was not required for this health services research project. Funding This project was funded by the Scottish Government and the Edinburgh Community Health Partnership of NHS Lothian. Acknowledgements We would like to acknowledge Tara Duthie (GUM) for help with data collection, Anne Lorimer (Pharmacy) and Laura Fleetham (Dean Terrace) for disseminating information to pharmacists, and Eilidh Fletcher (Public Health) for statistical assistance. j References 1 UK national guideline for the management of genital infection with Chlamydia trachomatis2006. [ 61/61.pdf]. Accessed 3 December Mercer CH, Sutcliffe L, Johnson AM, White PJ, Brook G, Ross JD, et al. How much do delayed health care seeking, delayed care provision and diversion from primary care contribute to the transmission of STI s? Sex Transm Infect 2007;83: Patton DL, Wolner Hanssen P, Cosgrove SJ, Holmes KK. The effects of Chlamydia trachomatis on the female reproductive tract of the macara memestrina after a single tubal challenge following repeated inoculations. Obstet Gynecol 1990;76: Centers for Disease Control and Prevention. [ legal/default.htm] Accessed 4 December Kissinger P, Mohammed H, Richardson-Alston G, Leichliter JS, Taylor SN, Martin DH. Patient-delivered partner treatment for male urethritis: a randomized controlled trial. Clin Infect Dis 2005;41: Golden MR, Whittington WLH, Handsfield HH, Hughes TP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005;352: Cameron ST, Glasier A, Scott G, Young H, Melvin L, Johnstone A, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomised controlled trial. Hum Reprod 2009;24: Cameron ST, Melvin L, Glasier A, Scott G, Johnstone A, Young H. Willingness of gynaecologists, doctors in family planning, gp s, practice nurses and pharmacists to adopt novel interventions for treating sexual partners of women with Chlamydia. BJOG 2007;114: Sexual health and hormonal contraception, module 5. NHS Education for Scotland. [ public_health/]. Accessed 1 March SIGN guideline no.109. Management of genital Chlamydia trachomatis infection. Scottish Intercollegiate Guideline network. March 2009 [ Accessed 1 March Cameron ST. Patient delivered partner therapy for Chlamydia- a realistic public health measure in the UK. BJOG 2009;116: ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
6 Pharmacy treatment for chlamydia 12 Baraitser P, Pearce V, Holmes J, Horne N, Boynton PM. Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health Care 2007;16: Manavi K, McMillan A, Young H. Genital infection in male partners of women with chlamydial infection. Int J STD AIDS 2006; 17: Melvin L, Cameron ST, Glasier A, Scott G, Johnstone A, Elton R. Preferred strategies of men and women for managing chlamydial infection. BJOG 2009;116: Health Protection Scotland Scotlands sexual health information. NHS Scotland. [ publications/sshi pdf]. Accessed 3 December Journal club Discussion points 1. Background: Describe the prevalence of genital infection with Chlamydia in your area as well as worldwide, and the implications for public health. Critically appraise the available evidence with regards to patient-delivered treatment versus partner notification versus selective screening for sexually transmitted infections, with reference to compliance, cost-effectiveness and patient satisfaction. Debate the differences between developing and developed countries, paying particular attention to cultural and practical issues. 2. Methodological considerations: In this study, the researchers relied on the reports of service users to assess the satisfaction of their partners: discuss. Debate the possible effect of spousal versus casual partners on the outcome measures. 3. Results and implications: Discuss possible serious adverse effects of patient-delivered treatment, both in general and comparing patient-delivered antibiotics with vouchers. The results of this study show fair compliance with the intervention, a process measure. Evaluate the use of process versus outcome measures to judge the effectiveness of healthcare interventions, using this study as an example for more general discussions. Brainstorm possible ways to improve the effectiveness, acceptability, equality and safety of patient-delivered treatment for the partners of people with sexually transmitted infections. j D Siassakos Southmead Hospital, Bristol, UK jsiasakos@gmail.com ª 2010 The Authors Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 1079
Preferred strategies of men and women for managing chlamydial infection
DOI: 10.1111/j.1471-0528.2008.01977.x www.blackwellpublishing.com/bjog Genitourinary medicine Preferred strategies of men and women for managing chlamydial infection L Melvin, a ST Cameron, a A Glasier,
More informationEvaluation of a Population-Based Program of Expedited Partner Therapy for Gonorrhea and Chlamydial Infection
Sexually Transmitted Diseases, August 2007, Vol. 34, No. 8, p.598 603 DOI: 10.1097/01.olq.0000258319.54316.06 Copyright 2007, American Sexually Transmitted Diseases Association All rights reserved. Evaluation
More informationAPPENDIX A SERVICE SPECIFICATION
Service Specification No. Service Authority Lead Provider Lead 2013/14 APPENDIX A SERVICE SPECIFICATION Participation in the Ruclear chlamydia and gonorrhoea screening programme (General practices) Period
More informationDr Claudia Estcourt. Barts and the London School of Medicine and Dentistry THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Claudia Estcourt Barts and the London School of Medicine and Dentistry 1-4 April 2014, Arena and Convention Centre Liverpool Preventing STI Re-infection
More informationNEW GENERAL MEDICAL SERVICES CONTRACT SPECIFICATION FOR THE PROVISION OF AN ENHANCED SERVICE SERVICE SPECIFICATION CHLAMYDIA SCREENING
NEW GENERAL MEDICAL SERVICES CONTRACT SPECIFICATION FOR THE PROVISION OF AN ENHANCED SERVICE SERVICE SPECIFICATION CHLAMYDIA SCREENING April 1, 2013 March 31, 2014 SERVICE CHLAMYDIA SCREENING REFERENCE
More informationRe-infection by untreated partners of people treated. for Chlamydia trachomatis and Neisseria gonorrhoeae:
Re-infection by untreated partners of people treated for Chlamydia trachomatis and Neisseria gonorrhoeae: mathematical modelling study Nicola Low, 1 Janneke Cornelia Maria Heijne, 1,2 Sereina Annik Herzog,
More informationChlamydia Screening strategy in the UKhow far have we come?
Chlamydia Screening strategy in the UKhow far have we come? Dr Janette Clarke Chair, National Chlamydia Screening Advisory Group Department of Health England Jan.clarke@leedsth.nhs.uk 13/01/2010 National
More information(and the arrested immunity hypothesis)
Partner notification (and the arrested immunity hypothesis) Dr. Nicola Low, MD FFPH Institute of Social and Preventive Medicine, University of Bern, Switzerland New Zealand Sexual Health Conference, Dunedin,
More informationTelford & Wrekin Pharmacy LES Chlamydia Screening Page 1 of 16
NATIONAL CHLAMYDIA SCREENING PROGRAMME LOCAL ENHANCED SERVICE (LES) SPECIFICATION FOR OPPORTUNISTIC CHLAMYDIA SCREENING PILOT IN PHARMACY April 2010 Telford & Wrekin Pharmacy LES Chlamydia Screening 2010-11
More informationExpedited Partner Therapy (EPT)/Patient Deliver Partner Therapy (PDPT)
Expedited Partner Therapy (EPT)/Patient Deliver Partner Therapy (PDPT) David Johnson STD Disparities Coordinator, Office of Health Equity Division of STD Prevention National Center for HIV, Viral Hepatitis,
More informationNational Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection
National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection UNCONTROLLED WHEN PRINTED EFFECTIVE FROM OCTOBER 2008 REVIEW DATE
More informationNHS Lothian Patient Group Direction Version: 006
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION AND SUPPLY OF AZITHROMYCIN FOR TREATMENT OF CHLAMYDIA (PATIENT OR PARTNER) OR CONTACTS OF NON-SPECIFIC URETHRITIS (NSU) OR PELVIC INFLAMMATORY DISEASE (PID)
More informationSTI & HIV screening in Primary Care. Dr Paddy Horner Consultant Senior Lecturer University of Bristol Annette Billing Public Health, Bristol Council
STI & HIV screening in Primary Care Dr Paddy Horner Consultant Senior Lecturer University of Bristol Annette Billing Public Health, Bristol Council Outline Why Screen Advances in diagnostics how can we
More informationSexual Health Services (Emergency Hormonal Contraception, Chlamydia Screening, Condom Distribution & Pregnancy Testing) in Pharmacies.
Local Enhanced Service (LES) Specification for: Sexual Health Services (Emergency Hormonal Contraception, Chlamydia Screening, Condom Distribution & Pregnancy Testing) in Pharmacies. 1. Introduction 2.
More informationBest Practices in STD Partner Management
Best Practices in STD Partner Management An Overview of Patient-Delivered Partner Therapy (PDPT) and Counseling for Partner Notification and Treatment Amber Eisenmann, MS Director of Learning Exchange
More informationFamily Planning Title X Chlamydia Screening Quality Improvement Project
Family Planning Title X Chlamydia Screening Quality Improvement Project Illinois Department of Public Health STD Section Staff March 22, 2017 Objectives Discuss current STD trends and epidemiology of chlamydia
More informationThe objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and
1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship
More informationCost-effectiveness of abandoning microscopy of urethral smears for asymptomatic nonchlamydial non-gonococcal urethritis in men in the UK
Cost-effectiveness of abandoning microscopy of urethral smears for asymptomatic nonchlamydial non-gonococcal urethritis in men in the UK Appendix 1 Model Assumptions All assumptions were confirmed and
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationNational Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection
National Patient Group Direction for the Supply of Azithromycin, by Pharmacists, for the Treatment of Uncomplicated Chlamydia Infection UNCONTROLLED WHEN PRINTED EFFECTIVE FROM NOVEMBER 2010 REVIEW DATE
More informationPatient-Delivered Partner Treatment for Male Urethritis: A Randomized, Controlled Trial
MAJOR ARTICLE Patient-Delivered Partner Treatment for Male Urethritis: A Randomized, Controlled Trial Patricia Kissinger, 1 Hamish Mohammed, 1 Gwangi Richardson-Alston, 1 Jami S. Leichliter, 3 Stephanie
More informationBarriers, Concerns, and Recommended Course of Action for Expedited Partner Therapy for the Treatment of Gonorrhea and Chlamydia
Barriers, Concerns, and Recommended Course of Action for Expedited Partner Therapy for the Treatment of Gonorrhea and Chlamydia 15 March 2012 MALPH EPT 2 Introduction What is expedited partner therapy?
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD
More informationCHLAMYDIA SCREENING ENHANCED SERVICE SERVICE SPECIFICATION. Page 1 of 12
CHLAMYDIA SCREENING ENHANCED SERVICE SERVICE SPECIFICATION www.best2know.co.uk Page 1 of 12 CONTENTS INTRODUCTION 3 AIMS OF THE SERVICE 4 SERVICE DETAILS 1. Who can access the service? 2. Referral into
More informationMultipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy
Multipurpose Prevention Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy Rapporteur: Craig Cohen (UCSF) Session Chairs: Carolyn Deal (NIH/NIAID) Anke Hemmerling
More informationProject Team. David Lewis Leela Barham
6 th September 2006 Economic of s to Reduce the Transmission of Chlamydia and other Sexually Transmitted and to Reduce the Rate of Under Eighteen Conceptions A Final Report for the National Institute for
More informationJulie Nelson RNC/WHNP-BC Epidemiology NURS 6313
Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313 Chlamydia Most frequently reported bacterial STI in the US In 2006, In U.S. 1,030,911 cases were reported. Estimated 2,291,000 infections in 14-39 year olds.
More informationabcdefghijklmnopqrstu
Chief Medical Officer Directorate Chief Medical Officer and Secretariat Division abcdefghijklmnopqrstu T: 0131-244 2399 F: 0131-244 2989 E: sandra.falconer@scotland.gsi.gov.uk NHS Board Medical and Nursing
More informationSTANDARD OPERATING PROCEDURE Chlamydia screening and treatment for year olds
STANDARD OPERATING PROCEDURE Chlamydia screening and treatment for 15-24 year olds Service Commencement Date: 1 st October 2014 Contract Term: 17 months to 31 st March 2016 Produced by: Leicestershire
More informationScottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018
Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018 Page 1 Contents 1 Introduction Page 3 2 Contact details Page 4 3 Opening hours Page 4 4 Services provided
More informationFY 2018 PERFORMANCE PLAN. Public Health/ CHSB
Sexually Transmitted Infections Clinic Public Health/ CHSB Lilibeth Grandas x1211 Sharron Martin x1239 Program Purpose Program Information Reduce and prevent the incidence of sexually transmitted infections
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More informationWarrington Centre for Sexual Health WCSH Local Enhanced Service LES
Warrington Centre for Sexual Health WCSH Local Enhanced Service LES 2015-19 NOTE: This LES is only for asymptomatic persons and does not cover testing and treatment of symptomatic persons Introduction
More informationPopulation Based KCIs Data for 2006
Key Clinical Indicators for Sexual Health: Population Based KCIs Data for 2006 Introduction...2 Chlamydia...3 Access to Male & Female Sterilisation...8 Female Sterilisation...8 Male Sterilisation / Vasectomy...11
More informationFREEDOM OF INFORMATION CHRONIC FATIGUE CLINIC
Date 21/09/2007 Your Ref Our Ref RM/602 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhb.scot.nhs.uk FREEDOM OF INFORMATION CHRONIC
More informationAccess to IVF. Help us decide Discussion paper. South Central Specialised Commissioning Group C - 1
Access to IVF Help us decide Discussion paper South Central Specialised Commissioning Group 1 C - 1 Access to IVF treatment Contents 1. Background 3 2. Developing a single policy for NHS South Central..4
More informationDisclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.
Disclosures Management of STIs: Challenges in Practice I have no disclosures or conflicts of interest to report. Alison O. Marshall, MSN, FNP-C Associate Professor of Practice & Director of the Family
More informationSTI Diagnostics Redesign. HVS and Chlamydia Resource Pack
Important! 1. This information is intended to support practitioners in the management of common sexual health problems and it is therefore essential that each doctor and nurse receives a copy. 2. Future
More informationCheshire and Merseyside Sexual Health Network STI Care Pathways explanatory document
Cheshire and Merseyside Sexual Health Network STI Care Pathways explanatory document Clinical STI/HIV Care Pathway assumes appropriate competency verified (flow chart and explanatory notes to be read together)
More informationSurvey questionnaire on STI. surveillance, care and prevention. in European countries SAMPLE APPENDIX
European Surveillance of Sexually Transmitted Infections Survey questionnaire on STI surveillance, care and prevention in European countries APPENDIX Detailed questionnaire on clinician and laboratory
More informationSexual health in adolescents in the UK: What do the data show? Dr Gwenda Hughes and Dr Anthony Nardone Health Protection Services Colindale
Sexual health in adolescents in the UK: What do the data show? Dr Gwenda Hughes and Dr Anthony Nardone Health Protection Services Colindale 30 November 2011 Overview Present data on sexual health in adolescents
More informationWomen & Children's Business Unit Maternity Contraception and Sexual Health
Women & Children's Business Unit Maternity Contraception and Sexual Health Author/s Contact name Approval process Obstetric Guidelines Group/Associate Medical Director First Issue Date Trust intranet ref:
More informationClinical Governance Advice No. 1d
Clinical Governance Advice No. 1d February 2010 DEVELOPMENT OF RCOG GREEN-TOP GUIDELINES: CONSENSUS METHODS FOR ADAPTATION OF GREEN-TOP GUIDELINES This is the second edition of Clinical Governance Advice
More informationService Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle
Service Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle Contents 1. Agreement period 2. Scope 3. Targets 4. Service outline 5. Support for clients using
More informationScreening & Treating Chlamydia in Primary Care. Wednesday, September 21, 2016
Screening & Treating Chlamydia in Primary Care Wednesday, September 21, 2016 We Want To Hear From You! Type questions into the Questions Pane at any time during this presentation Patient-Centered Primary
More informationSUBFERTILITY. (Defined as involuntary failure to conceive within 12 months with regular coitus)
SUBFERTILITY (Defined as involuntary failure to conceive within 12 months with regular coitus) Clients attending with fertility concerns should have a medical, drug, menstrual, contraception, social and
More informationSexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011
Sexually Transmitted Infection surveillance in Northern Ireland 2012 An analysis of data for the calendar year 2011 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:
More informationONLINE SUPPLEMENTARY MATERIALS: FILE 1
ONLINE SUPPLEMENTARY MATERIALS: FILE 1 Clinical care pathways using chlamydia and gonorrhoea tests are evolving: point of care nucleic acid amplification tests may reduce genitourinary medicine service
More informationevidence & practice / electronic assessments
POST TREATMENT Experiences and outcomes of lung cancer patients using electronic assessments Rose P, Quail H, McPhelim J et al (2017) Experiences and outcomes of lung cancer patients using electronic assessments.
More informationAction 12 Subgroup Report on the Baseline Data for 2005
DASH Project Key Clinical Indicators for Sexual Health: Action 12 Subgroup Report on the Baseline Data for 2005 Key Clinical Indicators for Sexual Health: Action 12 Report on the Baseline Data for 2005
More informationBarnet Scrutiny Committee report 13 th October Barnet Sexual Health Strategy Dr Andrew Howe, Director of Public Health
Barnet Scrutiny Committee report 13 th October 2015 Title Report of Wards Status Urgent Key Enclosures Officer Contact Details Barnet Sexual Health Strategy 2015-2020 Dr Andrew Howe, Director of Public
More informationSexual health commissioning Frequently asked questions Published February Health, adult social care and ageing
Sexual health commissioning Frequently asked questions Published February 2013 Health, adult social care and ageing Introduction These Frequently Asked Questions (FAQs) have been produced by the Local
More informationHIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015
HIV in the UK: Changes and Challenges; Actions and Answers The People Living With HIV Stigma Survey UK 2015 Scotland STIGMA SURVEY UK 2015 SCOTLAND The landscape for people living with HIV in the United
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME QOF indicator area: Epilepsy Briefing paper Potential output: Recommendations
More informationTrends in STDs: US Perspective. Michael Towns, M.D. WW Vice President, Medical Affairs BD Diagnostic Systems
Trends in STDs: US Perspective Michael Towns, M.D. WW Vice President, Medical Affairs BD Diagnostic Systems Outline Overview of STD Epidemiology and Current Situation in US Overview of Chlamydia infections
More informationGynaecology. Pelvic inflammatory disesase
Gynaecology د.شيماءعبداألميرالجميلي Pelvic inflammatory disesase Pelvic inflammatory disease (PID) is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis,
More informationWaverley Gate 2-4 Waterloo Place Edinburgh. Date 16/12/11 Your Ref Our Ref. Enquiries to Richard Mutch
Lothian NHS Board Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG Telephone 0131 536 9000 Fax 0131 536 9088 www.nhslothian.scot.nhs.uk Date 16/12/11 Your Ref Our Ref Enquiries to Richard Mutch Extension
More informationBriefing on new Sexual health and HIV services in Surrey
Briefing on new Sexual health and HIV services in Surrey Central and North West London NHS Foundation Trust (CNWL) took over the majority of Sexual Health and HIV treatment and care (outpatient) services
More informationFramework on the feedback of health-related findings in research March 2014
Framework on the feedback of health-related findings in research March 2014 Summary Scope and background In the course of a study involving human participants, researchers may make a finding that has potential
More informationEdinburgh Access Practice Hepatitis C Clinic Jessie Anderson, Kim McBeth, John Budd and Rebecca Martin
Edinburgh Access Practice Hepatitis C Clinic Jessie Anderson, Kim McBeth, John Budd and Rebecca Martin Content What is hepatitis C and why is it important? Brief overview of how the clinic works Have a
More information2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)
E10d 2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No.
More informationYoung People s Sexual Health Services. Pathways for Practitioners In Cambridgeshire
Young People s Sexual Health Services Pathways for Practitioners In Cambridgeshire vember 2013 Background Sexual Health and Contraceptive Services for young people operate in different settings and organisations
More informationNon-gonococcal urethritis. Looking after your sexual health
Non-gonococcal urethritis Looking after your sexual health 2 3 Non-gonococcal urethritis Urethritis is inflammation (pain, redness or soreness) of the urethra (the tube that carries urine out of the body).
More informationInfectious Diseases and Sexual Health in Southwark
Chapter 7 Infectious Diseases and Sexual Health in Southwark Introduction 7.1 The JSNA 2008 did not reflect the problems of infectious diseases and this chapter redresses this gap. Infectious diseases
More informationService Specification
Service Specification Chlamydia Screening Release: Final Date: 1 August 2010 Author: Steph Cook Head of Sexual Health Commissioning NHS Derby City Owner: Maureen Whittaker Associate Director of Public
More informationabcdefghijklmnopqrstu
Health Workforce Directorate Employment and Retention Division Dear Colleague Best Practice Guidance Hepatitis B infected healthcare workers and antiviral therapy abcdefghijklmnopqrstu CEL 38 (2009) Date
More informationUnderstanding our report and advice: Antimicrobial wound dressings (AWDs) for chronic wounds
Understanding our report and advice: Antimicrobial wound dressings (AWDs) for chronic wounds Health technology assessment report 13 December 2015 Healthcare Improvement Scotland 2015 Published December
More informationNRT Voucher redemption scheme service specification
NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed
More informationTRICHOMONAS VAGINALIS
TRICHOMONAS VAGINALIS What s New: There are no changes to this guideline. Introduction Trichomonas vaginalis (TV) is a flagellated protozoan that is a parasite of the genital tract. Due to site specificity,
More informationMedical gap arrangements - practitioner application
Medical gap arrangements - practitioner application For services provided in a licensed private hospital or day hospital facility (Private Hospital) only. Please complete this form to apply for participation
More informationNAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know
NAS NATIONAL AUDIT OF SCHIZOPHRENIA Second National Audit of Schizophrenia What you need to know Compiled by: Commissioned by: 2 October 2014 Email: NAS@rcpsych.ac.uk The National Audit of Schizophrenia
More informationACE Programme SOMERSET INTEGRATED LUNG CANCER PATHWAY. Phases One and Two Final Report
ACE Programme SOMERSET INTEGRATED LUNG CANCER PATHWAY Phases One and Two Final Report July 2017 Introduction This paper presents the learning and actions that have been generated from phase One and Two
More informationSurvey of networks and arrangements for HIV clinical care
1 of 6 20/08/2007 16:40 Survey of networks and arrangements for HIV clinical care Please ensure that you have read the [add link] invitation letter [/add link] before completing this survey. When you have
More informationExpiry Date: September 2009 Template Version: Page 1 of 7
GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationIntegrated Sexual Health and HIV Services. Dr Simon Edwards - Clinical Director Mark Maguire - Service Director
Integrated Sexual Health and HIV Services Dr Simon Edwards - Clinical Director Mark Maguire - Service Director Introduction Improving Health and Wellbeing and Health Promotion Services in Surrey Patient
More informationKeywords Health-related quality of life, EQ-5D, cross-sectional study, Chlamydia trachomatis, women s health
Original research article Health-related quality of life and Chlamydia trachomatis infection in sexually experienced female inner-city students: a community-based cross-sectional study International Journal
More informationStrategies to achieve STI control in South Africa Prof Remco Peters
Strategies to achieve STI control in South Africa Prof Remco Peters 4 th South African HIV Clinicians Society Conference 27th of October 2018 The spectrum of STIs This presentation has been slightly amended
More informationCHOOSING WISELY FOR KINGSTON PROPOSED CHANGES TO LOCAL HEALTHCARE - IVF
GOVERNING BODY LEAD: Fergus Keegan, Director of Quality, Kingston & Richmond CCGs REPORT AUTHOR: Sue Lear, Acting Deputy Director of Commissioning ATTACHMENT: AGENDA ITEM: D2 RECOMMENDATION: The Governing
More informationLarge increase in opportunistic testing for chlamydia during a pilot project in a primary health organisation
Large increase in opportunistic testing for chlamydia during a pilot project in a primary health organisation Sunita Azariah MBChB, FAChSHM, DPH; 1 Stephen McKernon MA, MSc, M DM; 2 Suzanne Werder RCpN,
More informationHALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page
HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO TREATMENT 3 4. DEFINITION
More informationForsyth County, North Carolina 2012 HIV/STD Surveillance Report
Forsyth County, North Carolina 2012 HIV/STD Surveillance Report Forsyth County Department of Public Health Division of Epidemiology and Surveillance 799 N. Highland Avenue Winston-Salem, NC 27102-0686
More informationPatient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules
October 2016 Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules This Patient Group Direction (PGD) is a specific written instruction for the supply and/or administration of nitrofurantoin
More informationThis paper outlines the engagement activity that took place, and provides key themes from the 57 written responses received.
Agenda item: 5.4 Subject: Presented by: Prepared by: Submitted to: Specialist Fertility Services Dr Dustyn Saint SNCCG Commissioning Team SNCCG Communications and Engagement Team SNCCG Governing Body Date:
More informationSexually Transmitted Infection, including HIV, Health Protection Scotland Slide Set
Sexually Transmitted Infection, including HIV, 213 Health Protection Scotland Slide Set Enhanced surveillance systems are employed to give more detailed information on the epidemiology of infectious syphilis
More informationMEN AND CHLAMYDIA EXECUTIVE SUMMARY. ...up to one in ten sexually active young people now infected. PUTTING MEN TO THE TEST
MEN S HEALTH FORUM REPORT ON MEN AND CHLAMYDIA EXECUTIVE SUMMARY...up to one in ten sexually active young people now infected. 2 The number of young people diagnosed with chlamydia has more than doubled
More informationTransmission from the Oropharynx to the Urethra among Men who have Sex with Men
MAJOR ARTICLE Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men who have Sex with Men Kyle T. Bernstein, 1 Sally C. Stephens, 1 Pennan M. Barry,
More informationAccess to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network
Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network Information for GPs, community pharmacists and district nurses First issued
More informationTesting, Treating and Managing STIs Dr Jean Irvine
Testing, Treating and Managing STIs Dr Jean Irvine 1 Chlamydia 2 3 Chlamydia: key facts Intracellular bacterial infection Sexually transmitted: Vaginal sex Anal sex?oral sex Most common bacterial STI in
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationGOVERNING BOARD. Assisted Conception (IVF): Review of access criteria. Date of Meeting 21 January 2015 Agenda Item No 13. Title
GOVERNING BOARD Date of Meeting 21 January 2015 Agenda Item No 13 Title Assisted Conception (IVF): Review of access criteria Purpose of Paper The SHIP (Southampton, Hampshire, Isle of Wight and Portsmouth)
More informationOverview of CDC Recommendations for Expedited Partner Therapy (EPT)
Overview of CDC Recommendations for Expedited Partner Therapy (EPT) Catherine Satterwhite, PhD, MSPH, MPH Epidemiologist Expedited Partner Therapy: Challenges & Opportunities for Effective Implementation
More informationDear Colleagues, EXTENSION OF PAUSE TO THE USE OF VAGINAL MESH
29/03/2019 NHS Improvement and NHS England Wellington House 133-155 Waterloo Road London SE1 8UG 020 3747 0000 www.england.nhs.uk www.improvement.nhs.uk To: Regional Directors, Trust Medical Directors,
More informationTerrence Higgins Trust Norfolk Chlamydia Screening Programme (NorfolkCSP)
Terrence Higgins Trust Norfolk Chlamydia Screening Programme (NorfolkCSP) Screening Site Handbook Version 6 June 2015 www.areyougettingit.com Version control table Version date Version no. Author/reviewer
More informationA Suite of Enhanced Services for. Prudent Structured Care for Adults with Type 2 Diabetes
An Enhanced Service for Prudent Structured Care for Adults with Type 2 Diabetes Page 1 A Suite of Enhanced Services for Prudent Structured Care for Adults with Type 2 Diabetes 1. Introduction All practices
More informationSYNDROMIC CASE MANAGEMENT OF STD
SYNDROMIC CASE MANAGEMENT OF STD Sexually Transmitted Diseases A Guide for Decision-makers, Health Care Workers, and Communicators WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC MANILA
More informationGuidance on the use of molecular testing for Neisseria gonorrhoeae in Diagnostic Laboratories 2011
Guidance on the use of molecular testing for Neisseria gonorrhoeae in Diagnostic Laboratories 2011 Molecular testing for gonorrhoea working group (see Appendix) Prepared by Kirstine Eastick March 2012-1
More informationForsyth County, North Carolina 2013 HIV/STD Surveillance Report
Forsyth County, North Carolina 2013 HIV/STD Surveillance Report Forsyth County Department of Public Health Division of Epidemiology and Surveillance 799 N. Highland Avenue Winston-Salem, NC 27102-0686
More informationAn economic evaluation of a school-based sexually transmitted disease screening program Wang L Y, Burstein G R, Cohen D A
An economic evaluation of a school-based sexually transmitted disease screening program Wang L Y, Burstein G R, Cohen D A Record Status This is a critical abstract of an economic evaluation that meets
More informationSources of repeat Chlamydia trachomatis infections:
Sources of repeat Chlamydia trachomatis infections: The importance of different sex partners revealed by a behavioral and molecular epidemiologic approach Linda M. Niccolai, PhD Associate Professor, Yale
More information